Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Iovance Biotherapeutics Inc (IOVA)

Iovance Biotherapeutics Inc (IOVA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,131,331
  • Shares Outstanding, K 279,833
  • Annual Sales, $ 1,190 K
  • Annual Income, $ -444,040 K
  • EBIT $ -459 M
  • EBITDA $ -430 M
  • 60-Month Beta 0.60
  • Price/Sales 2,457.07
  • Price/Cash Flow N/A
  • Price/Book 3.80

Options Overview Details

View History
  • Implied Volatility 93.97% ( -74.14%)
  • Historical Volatility 56.02%
  • IV Percentile 36%
  • IV Rank 19.99%
  • IV High 320.56% on 08/07/24
  • IV Low 37.36% on 08/15/24
  • Put/Call Vol Ratio 0.19
  • Today's Volume 11,544
  • Volume Avg (30-Day) 11,755
  • Put/Call OI Ratio 0.22
  • Today's Open Interest 221,305
  • Open Int (30-Day) 197,969

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.31
  • Number of Estimates 6
  • High Estimate -0.25
  • Low Estimate -0.35
  • Prior Year -0.46
  • Growth Rate Est. (year over year) +32.61%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.20 +23.11%
on 10/10/24
11.47 -1.26%
on 11/04/24
+0.87 (+8.28%)
since 10/04/24
3-Month
7.11 +59.30%
on 08/05/24
12.50 -9.39%
on 08/23/24
+3.54 (+45.39%)
since 08/02/24
52-Week
3.76 +201.22%
on 11/10/23
18.33 -38.21%
on 02/28/24
+7.12 (+169.03%)
since 11/03/23

Most Recent Stories

More News
Iovance Biotherapeutics to Host Third Quarter and Year-to-Date 2024 Financial Results Conference Call and Webcast on Thursday, November 7, 2024

IOVA : 11.36 (+1.52%)
Why Iovance Biotherapeutics Stock Triumphed on Thursday

With a cutting-edge melanoma drug now on the market, the company is positioned for a breakout.

IOVA : 11.36 (+1.52%)
UBS : 31.16 (+0.16%)
Is Iovance Biotherapeutics Stock a Buy?

The biotech is making important breakthroughs, but is that enough?

IOVA : 11.36 (+1.52%)
3 Reasons to Buy Iovance Biotherapeutics Stock Like There's No Tomorrow

This biotech's growth story is going to start moving faster, and soon.

IOVA : 11.36 (+1.52%)
3 Things You Need to Know if You Buy Iovance Biotherapeutics Today

There's plenty of upside with this stock, but it might take a while to realize.

IOVA : 11.36 (+1.52%)
This Is the Biggest Risk With Iovance Biotherapeutics Stock

Investors should brace for dilution.

IOVA : 11.36 (+1.52%)
3 Monster Biotech Stocks to Buy Before 2025

These companies are nearly in the sweet spot of risk versus reward in biotech.

IOVA : 11.36 (+1.52%)
CRSP : 51.53 (+1.52%)
Up 47% in 2024: Where Will Iovance Biotherapeutics Be in 5 Years?

This company's new cancer therapy is producing remarkable results, but the company is losing money at a frightening pace.

IOVA : 11.36 (+1.52%)
This 1 Big Risk Is Also 1 Big Opportunity for Iovance Biotherapeutics Stock

It could demonstrate a few capabilities that no other biotech has as of yet.

IOVA : 11.36 (+1.52%)
Why Iovance Biotherapeutics Shares Are Soaring Today

The biopharma company is proving its recently approved cancer therapy is marketable.

IOVA : 11.36 (+1.52%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strengthening short term outlook on maintaining the current direction.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Iovance Biotherapeutics is a clinical-stage pharmaceutical company primarily focused on the development and commercialization of novel T cell-based cancer immunotherapies. These immunotherapies use Generation 2 ('Gen 2') tumor infiltrating lymphocyte (TIL), which harnesses the power of a patient's own...

See More

Key Turning Points

3rd Resistance Point 12.02
2nd Resistance Point 11.61
1st Resistance Point 11.40
Last Price 11.36
1st Support Level 10.78
2nd Support Level 10.37
3rd Support Level 10.16

See More

52-Week High 18.33
Fibonacci 61.8% 12.76
Last Price 11.36
Fibonacci 50% 11.05
Fibonacci 38.2% 9.33
52-Week Low 3.76

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar